N
Nuria Barbarroja
Researcher at University of Córdoba (Spain)
Publications - 101
Citations - 3025
Nuria Barbarroja is an academic researcher from University of Córdoba (Spain). The author has contributed to research in topics: Inflammation & Antiphospholipid syndrome. The author has an hindex of 30, co-authored 89 publications receiving 2416 citations. Previous affiliations of Nuria Barbarroja include Carlos III Health Institute & University of Cambridge.
Papers
More filters
Journal ArticleDOI
Differential Lipid Partitioning Between Adipocytes and Tissue Macrophages Modulates Macrophage Lipotoxicity and M2/M1 Polarization in Obese Mice
Xavier Prieur,Crystal Y.L. Mok,Vidya Velagapudi,Vanessa Núñez,Lucía Fuentes,David Montaner,Ko Ishikawa,Alberto Camacho,Nuria Barbarroja,Stephen O'Rahilly,Jaswinder K. Sethi,Joaquín Dopazo,Matej Orešič,Mercedes Ricote,Antonio Vidal-Puig +14 more
TL;DR: The data indicate that the M1 ATM polarization in obesity might be a macrophage-specific manifestation of a more general lipotoxic pathogenic mechanism and indicates that strategies to optimize fat deposition and repartitioning toward adipocytes might improve insulin sensitivity by preventing ATM lipotoxicity and M1 polarization.
Journal ArticleDOI
Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF‐κB/Rel proteins via the p38 mitogen‐activated protein kinase pathway, and of the MEK‐1/ERK pathway
Chary López-Pedrera,Paula Buendía,Maria José Cuadrado,Emilio Siendones,Maria Angeles Aguirre,Nuria Barbarroja,Cristina Montiel-Duarte,Antonio Torres,Munther A. Khamashta,Francisco Velasco +9 more
TL;DR: The results suggest that aPL induces TF expression in monocytes from APS patients by activating, simultaneously and independently, the phosphorylation of MEK-1/ERK proteins, and the p38 MAP kinase-dependent nuclear translocation and activation of NF-kappaB/Rel proteins.
Journal ArticleDOI
The obese healthy paradox: is inflammation the answer?
Nuria Barbarroja,Rosario Lopez-Pedrera,María Dolores Mayas,Eduardo García-Fuentes,Lourdes Garrido-Sánchez,Manuel Macias-Gonzalez,Rajaa El Bekay,Antonio Vidal-Puig,Francisco J. Tinahones +8 more
TL;DR: The results support the concept that NIR-MO individuals lack the inflammatory response that characterizes the IR-MO patient and that IL-6, IL-1beta, ERK and NF-kappaB are important effectors that mediate the inflammation effects promoting insulin resistance.
Journal ArticleDOI
Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome.
M. J. Cuadrado,Paula Buendía,Francisco Velasco,M.A. Aguirre,Nuria Barbarroja,Luis Arístides Torres,Munther A. Khamashta,Chary López-Pedrera +7 more
TL;DR: In this paper, the authors analyzed the expression of VEGF and Flt-1 in monocytes of 55 primary antiphospholipid syndrome (APS) patients, and found that the expression was significantly inhibited by the p38 mitogenactivated protein kinase (MAPK) inhibitor SB203580.
Journal ArticleDOI
Neutrophils: Novel key players in Rheumatoid Arthritis. Current and future therapeutic targets.
Irene Cecchi,Iván Arias de la Rosa,Elisa Menegatti,Dario Roccatello,Eduardo Collantes-Estevez,Chary López-Pedrera,Nuria Barbarroja +6 more
TL;DR: The pathogenic role of neutrophils in RA, the effect of conventional treatments and biologic therapies, and the new, potential targets of neutophil-derived molecules for the treatment of RA are reviewed.